HRMY (Harmony Biosciences Holdings) Marketable Securities: $118.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HRMY Harmony Biosciences Holdings Inc HRMY
94 GF Score
Price $38.74
GF Value $46.81
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Harmony Biosciences Holdings Marketable Securities?

Harmony Biosciences Holdings HRMY +1.35% 94 Marketable Securities is $118.0 Mil as of Jun. 2026. GuruFocus rates HRMY with a GF Score™ of 94/100 and a GF Value™ of $46.81 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Harmony Biosciences Holdings's Marketable Securities for the quarter that ended in Jun. 2026 was $118.0 Mil.

Harmony Biosciences Holdings's annual Marketable Securities declined from Dec. 2023 ($41.8 Mil) to Dec. 2024 ($14.2 Mil) but then increased from Dec. 2024 ($14.2 Mil) to Dec. 2025 ($22.8 Mil).

Harmony Biosciences Holdings  (NAS:HRMY) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Harmony Biosciences Holdings Marketable Securities Related Terms

Harmony Biosciences Holdings Marketable Securities Historical Data

* Premium members only.

The historical data trend for Harmony Biosciences Holdings's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Harmony Biosciences Holdings Marketable Securities Chart

Harmony Biosciences Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial 0.00 79.33 41.80 14.19 22.84

Harmony Biosciences Holdings Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.22 25.58 22.84 51.52 118.02
HRMY
94GF Score
Harmony Biosciences Holdings Inc HRMY
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Harmony Biosciences Holdings Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $118.0 Mil mean?
Harmony Biosciences Holdings (HRMY) has a Marketable Securities of $118.0 Mil as of Jun. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Harmony Biosciences Holdings and its competitors.
Is Harmony Biosciences Holdings' Marketable Securities too high?
Harmony Biosciences Holdings' current Marketable Securities is $118.0 Mil. Overall, Harmony Biosciences Holdings has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Harmony Biosciences Holdings' Marketable Securities compare to SION and URGN?
Harmony Biosciences Holdings' Marketable Securities of $118.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Harmony Biosciences Holdings and its competitors. Harmony Biosciences Holdings's current Marketable Securities is $118.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harmony Biosciences Holdings stock overvalued right now?
Based on GuruFocus' analysis, Harmony Biosciences Holdings (HRMY) is currently considered Modestly Undervalued. The stock's GF Value™ is $46.81, compared to a current price of $38.74 — trading 17.2% below its estimated fair value. The current Marketable Securities is $118.0 Mil. Harmony Biosciences Holdings' overall GF Score™ is 94/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Harmony Biosciences Holdings (HRMY), the current Marketable Securities is $118.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Harmony Biosciences Holdings (HRMY) Overvalued in 2026?

Based on GuruFocus' analysis, Harmony Biosciences Holdings stock appears to be undervalued. The current stock price of $38.74 is trading 17.2% below its estimated GF Value™ of $46.81. GuruFocus considers Harmony Biosciences Holdings to be Modestly Undervalued.

Key valuation signals for HRMY:

  • Marketable Securities: $118.0 Mil
  • GF Value™: $46.81 vs. price of $38.74 (17.2% below fair value)
  • GF Score™: 94/100 with 2 warning signs

No single metric tells the full story. See the HRMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Harmony Biosciences Holdings Business Description

Address 630 W. Germantown Pike, Suite 215, Plymouth Meeting, PA, USA, 19462
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
94GF Score

Get the complete analysis for HRMY

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$38.74
Price
$46.81
GF Value